• 1.

    Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.

  • 2.

    Camargo RA, Tuon FF, Sumi DV, Gebrim EM, Imamura R, Nicodemo AC, Cerri GG, Amato VS, 2010. Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. Am J Trop Med Hyg 83: 515518.

    • Search Google Scholar
    • Export Citation
  • 3.

    Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA, 2007. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77: 266274.

    • Search Google Scholar
    • Export Citation
  • 4.

    Nonata R, Sampaio R, Marsden PD, 1997. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg 91: 77.

    • Search Google Scholar
    • Export Citation
  • 5.

    Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA, 2000. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 46: 341342.

    • Search Google Scholar
    • Export Citation
  • 6.

    Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA, 2009. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 23: 10261034.

    • Search Google Scholar
    • Export Citation
  • 7.

    Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.

    • Search Google Scholar
    • Export Citation
  • 8.

    Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477486.

    • Search Google Scholar
    • Export Citation
  • 9.

    Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377383.

    • Search Google Scholar
    • Export Citation
  • 10.

    Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R, 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 57: 11531160.

    • Search Google Scholar
    • Export Citation
  • 11.

    WHO, 2010. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, 2226 March 2010, Geneva.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 269 82 3
PDF Downloads 45 23 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?

View More View Less
  • Division of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo, Medical School, São Paulo, Brazil; Department of Infectious Diseases University of São Paulo, Medical School, São Paulo, Brazil; Division of Infectious and Parasitic Diseases, Hospital Universitário Evangélico de Curitiba, Curitiba, Paraná, Brazil; Laboratório de Investigação Médica-Parasitologia, Hospital das Clínicas, University of São Paulo, Medical School, São Paulo, Brazil
Restricted access

Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24–50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7–40 months).

Author Notes

*Address correspondence to Antonio Carlos Nicodemo, Department of Infectious Diseases, University of São Paulo, Medical School, Avenida Doutor Enéas de Carvalho Aguiar 255, 4° andar, sala 4028, 05403-000, São Paulo, SP, Brazil. E-mail: ac_nicodemo@uol.com.br

Authors' addresses: Valdir Sabaga Amato, Division of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo, Medical School, São Paulo, Brazil, E-mail: valdirsa@netpoint.com.br. Felipe Francisco Tuon, Division of Infectious and Parasitic Diseases, Hospital Universitário Evangélico de Curitiba, Curitiba, Paraná, Brazil, E-mail: flptuon@gmail.com. Raphael Abegão de Camargo, Department of Infectious Diseases University of São Paulo, Medical School, São Paulo, Brazil, E-mail: raphabegao@yahoo.com.br. Regina Maia Souza, Laboratório de Investigação Médica-Parasitologia, Hospital das Clínicas, University of São Paulo, Medical School, São Paulo, Brazil, E-mail: regina-maia@uol.com.br. Carolina Rocio Santos, Department of Infectious Diseases University of São Paulo, Medical School, São Paulo, Brazil, E-mail: carolnet83@hotmail.com. Antonio Carlos Nicodemo, Department of Infectious Diseases University of São Paulo, Medical School, São Paulo, Brazil, E-mail: ac_nicodemo@uol.com.br.

Save